EICHORCondition: Multifocal Motor Neuropathy · Sponsor: Dianthus Therapeutics
The purpose of this Phase 2 study is to evaluate the safety, tolerability, pharmacometrics, and efficacy of Claseprubart (DNTH103) in participants with multifocal motor neuropathy (MMN).
This description comes directly from the study's public registry record.
Dianthus Clinical Contact Center · 929-999-4055 · clinicaltrials@dianthustx.com
Always discuss trial participation with your own doctor first.
| Clinical Study Site | Scottsdale, Arizona, United States | Recruiting |
| Clinical Study Site | Los Angeles, California, United States | Recruiting |
| Clinical Study Site | Bradenton, Florida, United States | Recruiting |
| Clinical Study Site | Tampa, Florida, United States | Recruiting |
| Clinical Study Site | Honolulu, Hawaii, United States | Recruiting |
| Clinical Study Site | Kansas City, Kansas, United States | Recruiting |
| Clinical Study Site | Cincinnati, Ohio, United States | Recruiting |
| Clinical Study Site | Columbus, Ohio, United States | Recruiting |
| Clinical Study Site | Houston, Texas, United States | Recruiting |
| Cinical Study Site | Toronto, Canada | Recruiting |
| Cinical Study Site | Beijing, China | Recruiting |
| Clinical Study Site | Beijing, China | Recruiting |
+ 29 more locations — full list on the registry record.
Sponsor or site team? See the site landscape for this trial — listed sites, countries, and recruiting-density context.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06537999